ロード中...
Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
Hepatocellular carcinoma (HCC) is the second deadliest cancer worldwide, due to its high incidence and poor prognosis. Frequent initial presentation at advanced stages along with impaired liver function limit the use of a broad therapeutic arsenal in patients with HCC. Although main HCC oncogenic dr...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6884868/ https://ncbi.nlm.nih.gov/pubmed/31783782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0824-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|